Skip to main content
Premium Trial:

Request an Annual Quote

Cenix Inks Research Deal with Bayer

Premium

NEW YORK (GenomeWeb) – Cenix Biosciences this week announced that it has signed an agreement to provide RNAi-based high-content screening services to Germany's Bayer Pharma.

Cenix said the deal relates to a target discovery project for an undisclosed disease indication. Financial terms were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.